Lung Cancer Clinical Trial
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer
This is a phase II, open-label, single arm, single-stage study. Both, chemo-sensitive and chemo-resistant patients will be enrolled and treated with 4 cycles of combination of Guadecitabine and carboplatin
Male or female subjects, age â‰¥ 18 years.
Histological or cytological diagnosis of small cell lung cancer. Subjects must have extensive-stage disease is defined as disease beyond the ipsilateral hemithorax, mediastinum and ipsilateral supraclavicular area and including malignant pleural or pericardial effusion or hematogenous metastases.
Patient should not have received more than 1 prior line of chemotherapy (could have received immunotherapy which does not count as chemotherapy).
ECOG PS 0-1
Measurable disease as per RECIST v1.1. Subjects may have bone-only disease. NOTE: Bone-only subjects are eligible if their disease can be documented/evaluated by bone scans, CT or MRI. Their disease will be assessed using MD Anderson criteria. NOTE: Previously irradiated lesions are eligible as a target lesion only if there is documented progression of the lesion after irradiation.
Adequate bone marrow, liver, and renal function, as assessed by the following laboratory requirements:
Hemoglobin â‰¥ 9.0 g/dL
Absolute neutrophil count (ANC) â‰¥ 1,500/mm3
Platelet count â‰¥ 100,000/mm3
Total bilirubin â‰¤ 1.5 x upper limit of normal (ULN). For subjects with Gilbert's Disease, total bilirubin â‰¤ 3 x ULN
ALT and AST â‰¤ 2.5 x ULN. For subjects with documented liver metastases, ALT and AST â‰¤ 5Ã—ULN
International Normalized Ratio (INR) â‰¤1.5, if not therapeutically anticoagulated. Subjects who are being therapeutically anticoagulated may be included provided that the anticoagulation regimen is stable and closely monitored.
Estimated glomerular filtration rate (eGFR) â‰¥ 60 mL/minute/1.73 m2 as determined using the Cockcroft-Gault formula.
Women of child-bearing potential must not be pregnant or breastfeeding and must have a negative pregnancy test at screening.
Male and female subjects of child- bearing potential must agree to use an effective method of birth control from the screening visit through 6 months after the last dose of study drug.
Platinum refractory disease defined as disease progression during first line platinum containing chemotherapy regimen. Progression following platinum based therapy is allowed.
Prior therapy with a hypomethylating agent.
Previously untreated (non-irradiated), symptomatic brain metastases. No prior treatment is required for non-symptomatic brain metastases. Previously treated symptomatic brain metastases are permitted.
Unstable or clinically significant concurrent medical condition, psychiatric illness or social situation that would, in the opinion of the investigator, jeopardize the safety of a subject and/or their compliance with the protocol.
Clinically significant acute infection requiring systemic antibacterial, antifungal, or antiviral therapy. (Suppressive therapy for chronic infections allowed, for example: Subjects with HIV/AIDS with adequate antiviral therapy to control viral load would be allowed. Subjects with viral hepatitis with controlled viral load would be allowed while on suppressive antiviral therapy.)
Hypersensitivity to (IMP) or components of the study treatment regimen.
Treated with any investigational drug within 3 weeks of first dose of study treatment.
Pregnant or breastfeeding.
Second malignancy currently requiring active therapy except breast or prostate cancer stable on or responding to endocrine therapy.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Indianapolis Indiana, 46202, United States
Muncie Indiana, 47303, United States
Charlottesville Virginia, 22908, United States
Milwaukee Wisconsin, 53226, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.